No abstract available
Publication types
-
Case Reports
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / administration & dosage
-
Adenine / adverse effects
-
Adenine / analogs & derivatives
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cell Transdifferentiation* / genetics
-
Cell Transdifferentiation* / immunology
-
Cellular Reprogramming / genetics
-
Cellular Reprogramming / immunology
-
Cellular Reprogramming / physiology
-
Combined Modality Therapy
-
Epigenesis, Genetic / physiology
-
Epigenome / immunology
-
Gene Rearrangement
-
Genes, Immunoglobulin Heavy Chain / genetics
-
Humans
-
Immunotherapy / adverse effects*
-
Immunotherapy / methods
-
Lymph Nodes / pathology
-
Lymphoma, Mantle-Cell / genetics
-
Lymphoma, Mantle-Cell / immunology
-
Lymphoma, Mantle-Cell / therapy*
-
Neoplasms, Second Primary / diagnosis
-
Neoplasms, Second Primary / etiology*
-
Piperidines / administration & dosage
-
Piperidines / adverse effects
-
Receptors, Antigen, T-Cell / therapeutic use
-
Rituximab / administration & dosage
-
Rituximab / adverse effects
-
Sarcoma / etiology*
-
Sarcoma / genetics
-
Sarcoma / immunology
-
Sarcoma / pathology
-
Transplantation, Autologous / adverse effects
-
Tumor Cells, Cultured
Substances
-
CTL019 chimeric antigen receptor
-
Piperidines
-
Receptors, Antigen, T-Cell
-
ibrutinib
-
Rituximab
-
Adenine